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1. Introduction 
Liver failure is a devastating illness with extremely high morbidity and mortality. With the 
advent of life-saving orthotopic liver transplantation, the mortality and morbidity due to 
liver failure has been significantly reduced. Many patients awaiting transplant are critically 
ill. The intensive care management of patients before liver transplantation is aimed at 
optimizing hepatic and extrahepatic organ function before the transplant operation, with a 
goal to favorably influence the perioperative and postoperative graft and patient survival. 
Critical illness due to liver disease may present in the context of acute liver failure (ALF) or 
acute on chronic liver failure (ACLF). The differing pathophysiologic processes underlying 
these two categories of liver failure necessitate specific approaches to their intensive care 
management. In their extreme presentations, both types of liver failure result in multi-organ 
system failure; therefore, the intensive care management of these conditions requires a 
systematic multi-organ system approach to address hepatic and extrahepatic organ 
dysfunction (Ford et al., 2010). This chapter will provide a multi-organ system–based 
description of critical care management of ALF and ACLF before liver transplantation. 
2. Acute liver failure 
2.1 Definition and etiology 
Acute liver failure (ALF) represents a clinical syndrome of varying etiologies that ultimately 
manifests as hepatic encephalopathy and coagulopathy (International Normalized Ratio 
[INR] greater than 1.5) in the setting of acute liver dysfunction. By definition, coagulopathy 
and hepatic encephalopathy occur within 6 months following the initial symptoms of 
hepatic dysfunction in a patient without chronic liver disease. The timing of development of 
hepatic encephalopathy after an initial presentation of jaundice helps further subdivide ALF 
into categories of hyper-acute (hepatic encephalopathy developing within 7 days of onset of 
jaundice), acute (8-28 days), and sub-acute (29-84 days).  
The etiologies of ALF are numerous, and reversible causes must be actively sought. The 
most common etiology of ALF in the United States and United Kingdom is drug-induced, 
with acetaminophen toxicity the leading responsible agent. Other common classes of 
www.intechopen.com
 
Liver Transplantation – Basic Issues 
 
322 
medications known to provoke ALF in susceptible patients include antimicrobials, 
antidepressants, antiepileptics, anti-hypertensives, HIV therapy, chemotherapeutic agents, 
lipid-lowering agents, and glucose-lowering agents. Analgesics and recreational drugs are 
also known causes of drug-induced ALF.  
Additional etiologies of ALF include viral infections, including Hepatitis A, B, C, D, and E, 
as well as herpes simplex virus, varicella zoster virus, cytomegalovirus, and Epstein-Barr 
virus. Toxins responsible for ALF include amanita phyloides (mushrooms), herbal 
preparations, organic solvents, and bacterial toxins, such as bacillus cereus. Pregnancy-related 
conditions include the HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) 
and the acute fatty liver of pregnancy syndrome. Lymphoma, metastatic disease, hepatic 
ischemia, wilson disease, heat stroke, Budd-Chiari syndrome, autoimmune hepatitis, and 
extensive hepatic resection are other causes of ALF. Approximately 15-20% of patients with 
ALF have an undetermined cause. 
2.2 Diagnosis and initial management considerations in ALF 
Potential causes of ALF must be actively sought in the initial workup, as certain etiologies 
have specific life-saving treatments. Acetaminophen toxicity is treated with N-acetylcysteine, 
autoimmune hepatitis with corticosteroids, herpes simplex and varicella zoster viruses with 
intravenous acyclovir, acute fatty liver of pregnancy and HELLP syndrome by delivery of 
the fetus. Recent data suggests that the use of N-acetylcysteine (NAC) improves the 
outcome of patients with ALF, independent of the etiology (Lee et al., 2009). Many transplant 
centers advocate the use of NAC for all patients with ALF. NAC can be administered 
intravenously at a dose of 150 mg/kg over 15 minutes followed by 50 mg/kg over 4 hours, 
followed by 100 mg/kg over 16 hours. Adverse effects of NAC include bronchospasm and 
anaphylaxis and are managed by coadministration of antihistamines and corticosteroids as 
well as reduction of infusion rate. Oral preparations of NAC are also available. 
Discontinuation of NAC is appropriate following resolution of ALF or at the time of 
transplantation. 
In addition to ruling out reversible causes of ALF, exclusion of chronic liver disease is 
crucial for appropriate management. Physical examination of patients presenting with liver 
failure should therefore focus on stigmata of chronic liver disease, including abdominal 
ascites, spider angiomata, or caput medusae. Hepatic imaging with ultrasound, CT or MRI is 
useful to evaluate for the presence of portal hypertension and chronic liver disease, as well 
as to evaluate hepatic size and vasculature, ascites, and hepatic masses. Recommended 
laboratory testing for potential etiologies of ALF include autoimmune markers, viral 
serologies, toxicology screen, and serum and urine testing for copper overload.  
2.3 Patient stabilization 
All patients with ALF should be monitored and treated in an intensive care unit. Many 
patients have progressed to multi-organ failure upon arrival, and immediate supportive 
measures should be undertaken. These may include interventions such as endotracheal 
intubation and mechanical ventilation, intravenous fluid resuscitation, placement of arterial 
and central venous lines, and vasoactive agent support.  
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2.4 Organ-specific management 
2.4.1 Hepatic encephalopathy 
Hepatic encephalopathy is defined by the presence of neuropsychiatric symptoms in the 
absence of other causes of altered mental status. Mental status changes range from subtle 
cognitive impairments to frank coma. The impaired hepatic clearance of ammonia and other 
toxins are poorly tolerated in patients with ALF, and result in astrocyte swelling and 
cytotoxic cerebral edema. Hepatic encephalopathy is divided into four grades based on the 
West Haven Criteria (Atterbury et al., 1978); grade I denotes mild cognitive changes and 
attention deficits, grade II lethargy and apathy, grade III confusion and semi-stupor, and 
grade IV a comatose state.  
Hepatic encephalopathy in ALF can result in cerebral edema, herniation, and death. Any 
patient with ALF and altered mental status should undergo an emergent head CT to rule 
out cerebrovascular accident, intracranial hemorrhage, or mass effect prior to treatment of 
hepatic encephalopathy. Those with grade III or IV encephalopathy should undergo elective 
endotracheal intubation and mechanical ventilation for airway protection, with maintenance 
of adequate sedation and patient-ventilator synchrony to reduce sudden increases in 
intracranial pressure. Neurosurgical placement of an intraparenchymal pressure monitor 
should then be strongly considered in order to continuously monitor and treat elevated 
intracranial pressure.  
Intracranial hypertension is managed primarily with pharmacologic osmotherapy, with 
the goal to reduce intracranial pressure to less than 25 mmHg. Mannitol and hypertonic 
saline can be used for this purpose; if these measures fail, neuromuscular paralysis and 
therapeutic hypothermia with a target core body temperature of 32-33 degrees Celsius can 
be co-administered. In the setting of intracranial hypertension refractory to the above 
interventions, salvage therapy with barbiturate coma can be considered. Elevation of the 
head of the bed to 30 degrees is recommended for all patients. Furthermore, cerebral 
perfusion pressure, defined as the difference between mean arterial pressure and 
intracranial pressure, should be maintained at 60 mmHg or greater. In the setting of 
intracranial hypertension, this may require the use of vasoactive agents to increase the 
mean arterial pressure. Hyperventilation, formerly used to reduce intracranial pressure, 
may induce cerebral hypoxemia, and is no longer recommended for this purpose. Patients 
with grade I or II encephalopathy do not require intracranial pressure monitoring or 
endotracheal intubation for airway protection. However, serial neurologic exams are 
critical in these patients, as they can rapidly deteriorate to stage III or IV hepatic 
encephalopathy. 
2.4.2 Coagulopathy 
In addition to hepatic encephalopathy, coagulopathy, represented by an increasing INR, is a 
defining characteristic of progressing ALF. The synthetic function of the failing liver is 
diminished, and levels of clotting factors are reduced, resulting in elevations in the INR. In 
fact, the INR is considered the most sensitive indicator of hepatic function and is commonly 
used as a prognostic tool to aid prediction of spontaneous recovery or need for liver 
transplantation. Therefore, correction of the INR in the absence of bleeding is discouraged. 
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For invasive procedures, the INR can be temporarily corrected with recombinant Factor VIIa 
(Novo-7) at a dose of 40 μg/kg. Such therapy reduces the INR to below 1.5 within 30 
minutes of administration, and allows approximately 90-120 minutes for the performance of 
invasive procedures. Vitamin K may reduce the INR if malnutrition is contributing to 
coagulopathy.  
Despite the coagulopathic state observed in ALF, anticoagulant proteins such as protein  
C and S are reduced, and patients are at risk of venous thrombotic complications. 
Therefore, venous thromboembolism prophylaxis with subcutaneous heparin or low-
molecular weight heparin formulations should be considered despite the presence of 
coagulopathy. 
2.4.3 Renal impairment 
Acute kidney injury in ALF usually results from impaired renal perfusion or direct renal 
insults. Hepatorenal syndrome, which occurs in the setting of portal hypertension and 
chronic liver disease, does not occur in ALF. Management of acute kidney injury includes 
avoidance of additional nephrotoxic insults, as well as supportive measures. In order to 
avoid increases in intracranial pressure and significant fluid shifts, if renal replacement 
therapy is necessary, continuous renal replacement therapy (CRRT) is preferred over 
conventional hemodialysis. 
2.4.4 Infections 
Infections occur in ALF from functional immunosuppression. Patients are susceptible to 
overwhelming bacterial and fungal sepsis, although clinical signs of infection may be absent. 
Empiric antibacterial and antifungal therapy should be considered in the setting of 
advanced hepatic encephalopathy, shock, or for patients listed for transplantation. 
Associated sepsis and septic shock are managed with broad-spectrum antibiotics, vasoactive 
agent support and high-dose corticosteroids.  
2.4.5 Pulmonary complications 
Respiratory disturbances, including acute respiratory distress syndrome (ARDS) and acute 
lung injury (ALI), are frequent manifestations of ALF. In the setting of ALI and ARDS, lung-
protective strategies with low tidal volume (6 cc/kg ideal body weight) ventilator settings 
and mild permissive hypercapnea are recommended. Hypoxemic respiratory failure 
portends a poor prognosis and is treated supportively. Severe hypercapnea, bronchoscopy, 
and patient-ventilator asynchrony can exacerbate intracranial hypertension; titration of the 
set respiratory rate to compensate for hypercapnea, as well as adequate sedation and 
analgesia to improve synchrony, are imperative. Neuromuscular-blocking paralytic agents 
may be necessary if patient-ventilator asynchrony persists despite adequate sedation.  
2.4.6 Metabolic derangements 
Metabolic derangements result both from impaired hepatic metabolic function and resulting 
multi-organ failure. Consequences include lactic acidosis and disturbances in arterial pH, 
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glucose, and electrolytes. Hypoglycemia results from impaired gluconeogenesis and 
glycogenolysis, and is managed via dextrose infusion and frequent glucose monitoring. 
Electrolyte disturbances include hyponatremia, hypokalemia, hypomagnesemia, and 
hypophosphatemia, and should be corrected when recognized. However, the appearance of 
hypophosphatemia may indicate a favorable prognosis due to intracellular phosphorus 
consumption and hepatic regeneration. Finally, the high metabolic demands in ALF create a 
generalized catabolic state with resultant high nutritional needs. Enteric nutrition is 
recommended over parental routes to reduce gastrointestinal bacterial translocation and 
bleeding from stress ulceration. 
3. Acute on chronic liver failure 
3.1 Definition and etiology 
Acute on chronic liver failure (ACLF), or decompensated cirrhosis, occurs when cirrhosis of 
any etiology is complicated by the development and sequelae of portal hypertension. 
Longstanding portal hypertension results from intrahepatic resistance to portal flow, and 
increased portal inflow from inappropriate splanchnic vasodilation. These pathophysiologic 
changes result in splanchnic and systemic derangements, including the development of 
gastroesophageal varices, hepatic encephalopathy, pulmonary decompensation, and 
hepatorenal syndrome. Given the importance of splanchnic vasodilation in the 
pathophysiology of ACLF, pharmacologic therapy with splanchnic vasoconstrictors plays a 
central role in the therapy of ACLF. 
Etiologies of cirrhosis are numerous, and include alcoholic steatosis, chronic viral hepatitis, 
metabolic diseases (e.g. non-alcoholic fatty liver disease, hemachromatosis, wilson disease), 
autoimmune hepatitis and cholestatic liver diseases ( e.g. primary biliary cirrhosis and 
primary sclerosing cholangitis).  
3.2 Diagnosis  
The diagnostic workup of a patient with suspected cirrhosis is similar to that of a patient 
presenting with ALF. Physical examination may reveal stigmata of chronic liver disease, 
including ascites and splenomegaly. Abdominal imaging with CT or MRI provides 
radiographic confirmation of chronic portal hypertension. Non-hepatic causes of portal 
hypertension, such as cardiac cirrhosis from longstanding heart failure, should also be 
excluded.  
3.3 Organ-specific management 
3.3.1 Hepatic encephalopathy 
Hepatic encephalopathy in decompensated cirrhosis shares several qualities with the 
encephalopathy observed in ALF, including the grades of severity. However, major 
differences exist in clinical presentation and management of hepatic encephalopathy in 
ACLF. The chronicity of portal hypertension allows time for the development of ammonia 
fixation mechanisms and neuronal adaptation to ammonia. Thus, the hepatic 
encephalopathy of ACLF is not typically associated with cerebral edema. Treatment is 
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supportive and focuses on patient safety and avoidance of complications. As in ALF, 
patients with grade III or IV encephalopathy warrant elective intubation for airway 
protection. Causative factors of hepatic encephalopathy include dehydration, over-
diuresis, infection, use of benzodiazepines and narcotics, gastrointestinal bleeding, 
constipation, electrolyte or acid-base imbalances, or recent transjugular intrahepatic 
portosystemic shunt (TIPS) procedure. Progression of underlying liver disease may be  
the only identifiable precipitant; when reversible causes are identified, they should be 
treated.  
Medical treatment of hepatic encephalopathy consists of oral agents to assist in toxin 
elimination. Lactulose and other nonabsorbable disaccharides improve intestinal excretion 
of nitrogen and reduce production of ammonia by enteric bacteria. Intestinal decontamination 
with oral antibiotics such as rifaximin or metronidazole reduces the burden of ammonia-
producing bacteria.  
3.3.2 Gastroesophageal varices 
Hemorrhage due to gastroesophageal variceal bleeding can be imminently fatal, and 
requires emergent therapy. Airway protection with endotracheal intubation reduces  
the risk of aspiration during massive hematemesis. Intravenous volume resuscitation or 
blood products should be administered carefully, as excess volume can increase portal 
pressures and exacerbate bleeding. An appropriate post-transfusion hemoglobin goal is  
8 g/dL. 
Infusion of the somatostatin analogue octreotide reduces portal pressure and can induce 
splanchnic vasoconstriction and facilitate hemostasis during variceal bleeding. Terlipressin, 
a vasopressin analogue, has been used with success in Europe to help control variceal 
bleeding. All patients should receive prophylactic antibiotics with either ceftriaxone or a 
fluoroquinolone, which have been shown to reduce infections, reduce the risk of rebleeding, 
and improve survival (Bernard et al., 1999).  
Following initiation of pharmacologic therapy, definitive therapy for gastroesophageal 
varices requires upper endoscopy with endoscopic band ligation or sclerotherapy. If these 
measures fail, or if gastric varices are detected, urgent TIPS can be used to achieve 
hemostasis and prevent the development of new varices. For severe uncontrolled bleeding, 
esophageal balloon tamponade may be necessary for temporary stabilization until definitive 
TIPS therapy is undertaken.  
3.3.3 Cardiovascular impairments 
Cardiovascular system derangements frequently complicate the hemodynamic picture of 
decompensated cirrhosis. Circulatory changes resemble those of septic shock, including 
increased cardiac output, reduced systemic vascular resistance, wide pulse pressure, and 
decreased mean arterial pressure. Patients are susceptible to sepsis-induced hypotension 
and septic shock. Norepinephrine is the preferred vasoactive agent in such patients, as it 
preserves cardiac output while increasing vascular resistance. Hypotension can also occur 
by decreased venous return if severe ascites produces compression of the inferior vena cava. 
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Finally, the phenomenon of cirrhotic cardiomyopathy with impaired systolic and diastolic 
dysfunction, and reduced response to inotropic therapy has been described (Zardi et al., 
2010). Several mechanisms for cirrhotic cardiomyopathy have been proposed, including 
myocardial apoptosis, involvement of circulating carbon monoxide and nitric oxide, and 
cardiomyocyte receptor impairments. If overt heart failure develops, consultation with a 
cardiologist is advisable. 
3.3.4 Pulmonary complications 
The pulmonary system derangements in decompensated cirrhosis are characterized by distinct 
disorders of varying severity. In the hepatopulmonary syndrome (HPS), excess vasodilation of 
the pulmonary vasculature system limits oxygen diffusion across the alveolar-capillary 
membrane. Vasodilation may occur through nitric oxide and other circulating vasodilators, 
or through arteriovenous malformations resulting in intrapulmonary shunts; the difference 
in these two mechanisms distinguish type I and type II HPS, respectively. Presenting 
symptoms include dyspnea, platypnea, orthodeoxia, cyanosis, and hypoxemia. Arterial 
blood gas and transthoracic double bubble echocardiogram or lung perfusion scans can help 
establish the diagnosis. Supplemental oxygen improves hypoxemia in type I HPS, whereas 
embolization of arteriovenous malformations can be performed in type II syndrome. In both 
forms, liver transplantation is the definitive treatment, and the presence of either form 
facilitates priority listing for transplantation.  
Portopulmonary hypertension (PPH) is a form of pulmonary arterial hypertension occurring in 
the presence of portal hypertension, and portends a poor prognosis. The mechanism of the 
adverse effects of portal hypertension on the pulmonary vasculature remains unclear. 
Proposed explanations include endothelial remodeling in response to a hyperdynamic 
circulation, as well as inflammatory cascades related to cytokines. Patients present with 
exertional dyspnea, fatigue, chest pain, and signs of volume overload. Diagnosis is 
confirmed by right heart catheterization, which demonstrates a pulmonary artery pressure 
(PAP) of 25 mmHg or greater with a normal pulmonary capillary wedge pressure. The 
degree of PAP elevation correlates with mortality during liver transplant, and patients with 
moderate or severely elevated pressures generally are not candidates for transplantation. 
Continuous infusion of vasodilatory prostaglandins such as epoprostenol may improve 
hemodynamics and reduce PAP to allow patients improved likelihood of tolerating 
transplantation.  
Hepatic hydrothorax refers to pleural effusions that occur when diaphragmatic defects allow 
the transudation of ascitic fluid into the pleural space. Dyspnea, cough, chest discomfort, 
and respiratory collapse can occur. Diagnostic and therapeutic thoracentesis should be 
performed to exclude infection, malignancy, and cardiopulmonary etiologies of pleural 
effusions. Diuretics such as furosemide and spironolactone can be administered, but 
patients with respiratory compromise should undergo therapeutic thoracentesis. Chest 
tubes are contraindicated in hepatic hydrothorax, as re-expansion pulmonary edema and 
hypovolemic shock can occur and are poorly tolerated in the cirrhotic patient. If hepatic  
hydrothorax is refractory to diuresis and thoracentesis, TIPS is indicated to help prevent the 
formation of ascites and subsequent transudation. 
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3.3.5 Renal impairments 
Hepatorenal syndrome (HRS) is defined as an increase in creatinine to greater than 1.5 g/dL or 
a decrease in creatinine clearance to below 40 mL/min. HRS is a dreaded complication of 
cirrhosis, and can develop unexpectedly at any point in the course of illness. Splanchnic 
vasodilation in the setting of cirrhosis results in reduced effective blood volume and pre-
renal acute kidney injury. HRS is a diagnosis of exclusion. Two forms exist; type I 
progresses rapidly, whereas type II progresses over a longer time period; both are fatal 
without transplant. When diagnosing HRS, other causes of acute kidney injury in cirrhosis 
must be excluded, including dehydration and over-diuresis, medication effects, and intrinsic 
renal insults. Diagnostic criteria for HRS include: cirrhosis with ascites, creatinine level of at 
least 1.5 mg/dL, lack of response to diuretic withdrawal and volume expansion, absence of 
shock, and absence of nephrotoxic and parenchymal renal etiologies.  
A definitive curative treatment for HRS is limited to liver transplantation, but supportive 
measures aimed at correcting the pathophysiology are in trial. Terlipressin has been studied 
for HRS in addition to its use in variceal hemorrhage, and has demonstrated the ability to 
reverse Type 1 HRS. Octreotide and the alpha agonist midodrine can induce splanchnic 
vasoconstriction, thereby potentially reversing the pathophysiology of HRS. Avoidance of 
additional renal insults, including diuretics and other nephrotoxic agents, is essential. The 
TIPS procedure can be used to improve overall circulatory function through portal venous 
decompression. Finally, renal replacement therapy is often required while patients await 
transplant. 
3.3.6 Infectious complications 
Further complications of decompensated cirrhosis include a predisposition to infections, 
owing to a chronic low-grade inflammatory state produced by excess cytokines and reduced 
clearance of toxins. Impaired function of macrophages and antigen presenting cells and 
decreased levels of complement are also implicated. In the setting of septic shock, early goal-
directed therapy is warranted, but over-resuscitation of volume can increase portal 
pressures and lead to exacerbation of portal hypertension. As in acute liver failure, patients 
with decompensated cirrhosis may benefit from use of glucocorticoids to supplement 
vasoactive agents (Fernandez et al., 2006). Bacterial pathogens are most typical, but fungal 
infections occur frequently in cirrhosis and should be considered in the differential 
diagnosis. 
3.3.7 Ascites 
Abdominal ascites is another notable manifestation of decompensated cirrhosis. Ascites  
can cause significant morbidity, including abdominal pain and discomfort, dyspnea and 
orthopnea, hepatic hydrothorax, spontaneous bacterial peritonitis, and abdominal 
compartment syndrome. Abdominal compartment syndrome is characterized by restrictive 
lung mechanics, renal and mesenteric vascular compromise, and hypotension due to 
compression of the inferior vena cava.  
Ascites develops in response to renal hypoperfusion, which results in upregulation of the 
renin-angiotensin-aldosterone system to increase sodium and water retention. Elevated 
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portal pressures produce a capillary hydrostatic pressure gradient, forcing fluid into the 
abdominal interstitium. Sodium restriction and use of diuretics can be used to manage 
ascites. Refractory ascites can be managed with serial large-volume paracentesis or 
placement of a TIPS shunt. 
3.3.8 Spontaneous bacterial peritonitis 
Spontaneous bacterial peritonitis (SBP) is a frequent complication of ascites, and can precipitate 
hepatorenal syndrome. Common pathogens of SBP include E coli, K pneumonia, and S 
pneumococcus, although culture-negative SBP occurs as well. Recommended antibiotics 
include third-generation cephalosporins or fluoroquinolones; daily maintenance antibiotics 
are used for secondary prophylaxis. If SBP is suspected, treatment with antimicrobials while 
awaiting culture results is appropriate.  
4. Indications for liver transplantation 
Many patients with worsening ALF or ACLF are eligible for orthotopic liver transplant. 
Indications for transplant are numerous and include acquired or congenital etiologies, viral 
hepatitis, drug-induced ALF, cirrhosis, cholestatic diseases, metabolic disorders, vascular 
derangements, and hepatocellular carcinoma. Because the supply of donor grafts is 
exceeded by the demand for transplantation, organ allocation is critical. The process of 
organ allocation is defined by country-specific donor and recipient allocation schemes. 
Several models for prognostic data in ALF have been proposed. Consensus exists in the 
belief that the degree and clinical trend of coagulopathy and hepatic encephalopathy remain 
the most important prognostic indicators, and are helpful in determining patient 
appropriateness for transplantation listing. ALF may resolve with supportive treatment, but 
frequently progresses to death in the absence of transplantation. Patients with ALF therefore 
have highest priority for liver transplantation. 
Patients with decompensated cirrhosis are classified by the Model For End Stage Liver 
Disease (MELD) score (Murray and Carithers, 2005), which has largely replaced the Childs 
Pugh system, with higher MELD scores indicating higher mortality. Although exceptions 
are made, including for hepatocellular carcinoma, a MELD score of 15 or higher is generally 
required to list patients with end stage liver disease for transplantation.  
Several contraindications for transplantation exist. Active alcohol or substance abuse, 
medical non-adherence, poor social support, extrahepatic malignancy, significant 
cardiopulmonary disease, uncontrolled sepsis, extrahepatic systemic infections, and 
uncontrolled psychiatric illness are examples of contraindications to liver transplantation.  
5. Salvage mechanisms and bridges to transplant 
Although liver transplantation is life-saving for acute and chronic liver failure, the 
immunosuppressant medications necessary to prevent rejection and allow optimal graft 
function following transplant are frequently accompanied by adverse metabolic effects, 
nephrotoxicity, and susceptibility to potentially fatal infections. In addition, the demand for 
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transplant greatly exceeds the supply of donor livers, and many patients either die while 
awaiting a donor or become too critically ill to qualify for transplant. The discrepancy in  
the supply and demand for organs, and the high pre-transplant mortality and post-
transplant morbidity have generated interest in surgical techniques to avoid transplantation 
and chronic immunosuppression, and support systems to serve as a bridge to transplant or 
spontaneous recovery. Examples of these include auxiliary liver transplantation and liver 
assist devices. 
5.1 Auxiliary liver transplantation 
An alternative to traditional orthotopic liver transplantation for patients with ALF is  
that of auxiliary transplant, based on the well-established regenerative capacity of 
hepatocytes. Unlike traditional transplantation, where native hepatectomy is performed 
simultaneously with donor engraftment, in auxiliary transplants, the patient’s native liver 
is left surgically intact, while a partial or smaller sized donor graft is transplanted. This 
procedure allows assumption of hepatic functions by the donor graft, resolution of multi-
organ failure, and clinical stabilization of the patient. In turn, the native liver benefits  
both from additional time, as well as improved physiological conditions, thus maximizing 
the opportunity for hepatic regeneration. Younger patients (below 40 years of age) with 
ALF due to viral hepatitis or acetaminophen toxicity appear to have the best outcome 
with this strategy. After native hepatic function is demonstrated, the auxiliary graft can  
be removed, but is most frequently allowed to atrophy by withdrawal of 
immunosuppression. Complete cessation of immunosuppression can be achieved in many 
patients (Boudjema et al., 1995). 
5.2 Artificial and bioartificial hepatic support systems 
Mechanical hepatic support systems serve as a bridge to transplant in patients with ACLF, 
and as a bridge to transplant or spontaneous recovery in patients with ALF. These systems 
are designed to reproduce the detoxifying functions of the liver, and mimic the principles 
upon which renal replacement therapy is based. While conventional renal dialysis removes 
small toxins and water-soluble toxins, the liver detoxifies larger toxins and protein-bound 
toxins. Dialysis of these larger and protein-bound toxins through unbound human albumin 
solutions allows the removal from the patient’s circulation.  
Several artificial systems have been developed utilizing albumin dialysis. The Molecular 
Adsorbent Recirculating System (MARS), Single Pass Albumin Dialysis (SPAD), and 
Prometheus are examples; of these, MARS has been the most widely studied. MARS has 
been utilized for management of hepatic encephalopathy, cerebral edema, hepatorenal 
syndrome, treatment of drug overdoses, and as a bridge to transplantation (Mitzner, 2011). 
MARS has been shown to improve hemodynamic parameters and organ perfusion during 
circulatory collapse, and has been associated with improvement in hepatic synthetic 
function. For patients with ACLF, MARS can provide temporarily relief of intractable 
pruritis and fatigue. 
Bioartificial systems work similarly to artificial systems to remove toxins by albumin 
dialysis, but additionally utilize human or porcine hepatocytes to mimic hepatic synthetic 
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function. Advances in the development of bioartificial systems have been limited by the 
challenges in maintaining hepatocyte viability.  
6. Conclusion 
Acute liver failure and acute on chronic liver failure are complex illnesses often culminating 
in multi-organ failure, and require meticulous care in the pre-transplant phase. Mortality in 
the absence of transplantation is high, but the advent of multi-disciplinary critical care has 
significantly improved the outcome in these disease processes. A protocolized approach to 
the intensive care management of patients prior to liver transplantation will favorably 
impact the pre-transplant and post-transplant status of these patients. 
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